FilingReader Intelligence
Jumpcan Pharmaceutical resumes trading after takeover, drug approval
July 20, 2025 at 07:59 AM UTC•By FilingReader AI
Hubei Jumpcan Pharmaceutical's tender offer by Cao Fei concluded with the acquisition of 16,300 shares, giving him direct and indirect control of 56.07% of the company.
The company also received a drug registration certificate for Masenlosavir tablets, adding to its product pipeline. Shares resume trading July 21.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement by Hubei Jichuan Pharmaceutical Co., Ltd. regarding its collaborative product, MaseLoxaWe tablets, obtaining a drug registration certificateJuly 20, 2025 at 08:00 AM UTC
Hubei Jichuan Pharmaceutical Company Limited: liquidation announcement regarding Mr. Cao Fei's tender offer for company sharesJuly 20, 2025 at 08:00 AM UTC
SSE:600566•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Hubei Jumpcan Pharmaceutical publishes news
Free account required • Unsubscribe anytime